The dynamics of the cutaneous lupus erythematosus market are anticipated to change in the coming years owing to the expected launch of emerging therapies. The rising research and prevalence, along with the emergence of novel therapies, will fuel the cutaneous lupus erythematosus market during the forecast period of 2023–2032.
LAS VEGAS, Aug. 29, 2023 /PRNewswire/ -- DelveInsight's Cutaneous Lupus Erythematosus Market Insights report includes a comprehensive understanding of current treatment practices, cutaneous lupus erythematosus emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan] and China.
Key Takeaways from the Cutaneous Lupus Erythematosus Market Report
- As per DelveInsight analysis, the cutaneous lupus erythematosus market size in the 7MM and China was approximately USD 580 million in 2022 and it is expected to grow positively at a significant CAGR during the study period (2019–2032).
- As per the DelveInsight estimates, in 2022, the total diagnosed prevalent cases of cutaneous lupus erythematosus were around 1.4 million cases in the 7MM and China, which are expected to grow during the study period, i.e., 2019-2032.
- Globally, leading cutaneous lupus erythematosus companies such as Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth Therapeutics, Zylo Therapeutics, Sanofi, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, and others are developing novel cutaneous lupus erythematosus drugs that can be available in the cutaneous lupus erythematosus market in the coming years.
- Some key therapies for cutaneous lupus erythematosus treatment include Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, and others.
Discover which therapies are expected to grab the major cutaneous lupus erythematosus market share @ Cutaneous Lupus Erythematosus Market Report
Cutaneous Lupus Erythematosus Overview
Cutaneous lupus erythematosus (CLE) is a subtype of lupus erythematosus, an autoimmune disorder that primarily affects the skin. Cutaneous lupus erythematosus specifically targets the skin, causing a range of distinctive symptoms and manifestations. The exact cause of CLE is not fully understood, but it is believed to result from a complex interplay of genetic predisposition, environmental triggers, and immune system dysfunction.
Cutaneous lupus erythematosus symptoms can vary widely and often depend on the specific subtype, which includes discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and tumid lupus erythematosus (TLE). Common symptoms include skin rashes, lesions, and sensitivity to sunlight. The characteristic butterfly-shaped rash across the cheeks and nose, known as malar rash, is often associated with lupus. Diagnosing cutaneous lupus erythematosus involves a combination of clinical evaluation, medical history assessment, and laboratory tests. Dermatologists and rheumatologists may collaborate in the diagnostic process. Skin biopsies of affected areas can reveal specific histopathological features that help differentiate CLE from other skin conditions. Blood tests, such as antinuclear antibody (ANA) testing, can also assist in confirming the diagnosis and ruling out systemic involvement.
Cutaneous Lupus Erythematosus Epidemiology Segmentation
As per the DelveInsight estimates, in 2022, the total tumor prevalent cases of CLE by gender were around 347K and 1.1 million cases for males and females, respectively, in the 7MM and China, which are expected to grow during the study period, i.e., 2019─2032.
The cutaneous lupus erythematosus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM and China segmented into:
- Total Diagnosed Prevalent Cases
- Total Prevalent Cases of CLE by Gender
- Total Prevalent Cases of CLE by Type
- Total Treated Cases
- Total Prevalent Cases of CLE by Severity
Cutaneous Lupus Erythematosus Treatment Market
Cutaneous lupus erythematosus treatment is a nuanced process that takes into account the diverse clinical presentations and underlying immune mechanisms of the disorder. For patients with mild, localized forms of CLE, topical therapies like corticosteroid creams, calcineurin inhibitors, and retinoids can be beneficial in reducing inflammation and controlling symptoms. Antimalarial medications, such as hydroxychloroquine, are considered a cornerstone of CLE treatment due to their ability to modulate the immune response and mitigate skin manifestations. In cases of more extensive or persistent CLE, systemic treatments may be necessary. Immunosuppressive drugs like methotrexate, azathioprine, mycophenolate mofetil, and cyclosporine can help manage the immune dysfunction that triggers skin symptoms. Biologic agents, which target specific components of the immune system, are emerging as potential options for severe or treatment-resistant cases.
However, the cutaneous lupus erythematosus treatment landscape is complex and evolving. Therapeutic choices are tailored to the individual's subtype, symptom severity, and overall health. Additionally, patient education on sun protection and skin care remains a crucial aspect of CLE management, as ultraviolet light can exacerbate symptoms. Multidisciplinary collaboration between dermatologists, rheumatologists, and other healthcare providers ensures a comprehensive approach to care, addressing not only the physical symptoms but also the psychological and emotional aspects of living with a chronic autoimmune condition like CLE. Regular monitoring and adjustment of treatment plans, along with ongoing research efforts, contribute to refining the strategies for managing cutaneous lupus erythematosus.
To know more about cutaneous lupus erythematosus treatment, visit @ Cutaneous Lupus Erythematosus Treatment Drugs
Key Cutaneous Lupus Erythematosus Therapies and Companies
- Litifilimab: Biogen
- Daxdilimab: Horizon Therapeutics
- SOTYKTU (deucravacitinib): Bristol-Myers Squibb
- Edecesertib: Gilead Sciences
- DS-7011a: Daiichi Sankyo, Inc.
- Enpatoran: EMD Serono
Learn more about the FDA-approved drugs for cutaneous lupus erythematosus @ Drugs for Cutaneous Lupus Erythematosus Treatment
Cutaneous Lupus Erythematosus Market Dynamics
The cutaneous lupus erythematosus market dynamics have undergone a significant transformation in recent times. This relatively understudied facet of lupus, primarily affecting the skin, has gained recognition due to heightened awareness and improved diagnostic techniques. The growing prevalence of autoimmune disorders, including CLE, has prompted pharmaceutical companies to invest in research and development endeavors targeting innovative treatment approaches. Clinicians and patients alike are advocating for therapies that not only alleviate the visible symptoms of skin involvement but also address the underlying immune dysregulation.
The advent of precision medicine has fueled the exploration of targeted interventions, such as monoclonal antibodies and Janus kinase (JAK) inhibitors, tailored to counteract specific immune pathways driving CLE. These advancements, although promising, come with challenges like high development costs and the need for comprehensive clinical trials to establish efficacy and safety profiles. Additionally, the cutaneous lupus erythematosus market dynamics are influenced by the demand for non-pharmacological interventions, such as photoprotective measures and lifestyle modifications, which form an integral part of holistic CLE management.
Despite increased attention, the limited understanding of CLE's intricate pathophysiology remains a significant hurdle. The complexity of immune system dysregulation specific to skin involvement presents challenges in identifying suitable drug targets and developing precise interventions. Additionally, the lack of standardized diagnostic criteria for various CLE subtypes can delay accurate diagnosis and initiation of appropriate treatment.
Limited awareness and knowledge among healthcare professionals regarding CLE's diverse manifestations can lead to misdiagnosis or underdiagnosis, affecting patient access to timely and proper care. This is exacerbated by the scarcity of dedicated treatment guidelines, leading to variations in therapeutic approaches. Moreover, as the cutaneous lupus erythematosus market moves towards personalized medicine, the challenge of developing treatments that can cater to the genetic and immunological diversity of CLE patients becomes evident.
Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] and China |
Cutaneous Lupus Erythematosus Market Size in 2022 | USD 580 Million |
Key Cutaneous Lupus Erythematosus Companies | Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth Therapeutics, Zylo Therapeutics, Sanofi, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, and others |
Key Cutaneous Lupus Erythematosus Therapies | Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, and others |
Scope of the Cutaneous Lupus Erythematosus Market Report
- Therapeutic Assessment: Cutaneous Lupus Erythematosus current marketed and emerging therapies
- Cutaneous Lupus Erythematosus Market Dynamics: Conjoint Analysis of Emerging Cutaneous Lupus Erythematosus Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Cutaneous Lupus Erythematosus Market Access and Reimbursement
Discover more about cutaneous lupus erythematosus drugs in development @ Cutaneous Lupus Erythematosus Clinical Trials
Table of Contents
1. | Cutaneous Lupus Erythematosus Market Key Insights |
2. | Cutaneous Lupus Erythematosus Market Report Introduction |
3. | Cutaneous Lupus Erythematosus Market Overview at a Glance |
4. | Cutaneous Lupus Erythematosus Market Executive Summary |
5. | Disease Background and Overview |
6. | Cutaneous Lupus Erythematosus Treatment and Management |
7. | Cutaneous Lupus Erythematosus Epidemiology and Patient Population |
8. | Patient Journey |
9. | Cutaneous Lupus Erythematosus Marketed Drugs |
10. | Cutaneous Lupus Erythematosus Emerging Drugs |
11. | Seven Major Cutaneous Lupus Erythematosus Market Analysis |
12. | Cutaneous Lupus Erythematosus Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Cutaneous Lupus Erythematosus Pipeline
Cutaneous Lupus Erythematosus Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cutaneous lupus erythematosus companies, including Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, among others.
Cutaneous Lupus Erythematosus Epidemiology
Cutaneous Lupus Erythematosus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted cutaneous lupus erythematosus epidemiology in the 7MM.
Systemic Lupus Erythematosus Market
Systemic Lupus Erythematosus Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key systemic lupus erythematosus companies, including GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma, Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, among others.
Systemic Lupus Erythematosus Pipeline
Systemic Lupus Erythematosus Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cutaneous-lupus-erythematosus-market-is-expected-to-surge-at-a-cagr-of-7-2-by-2032--assesses-delveinsight-301912105.html
Voltar noticias em Inglês